Regeneron Pharmaceuticals, Inc.
May 11, 2010

Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series

TARRYTOWN, N.Y., May 11, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will participate in the J. P. Morgan Biotech: CEO/CFO Conference Call Series at 10:00 a.m. Eastern Time on Friday, May 14, 2010.

Conference call details are as follows:

A recording of the call will be available for telephone replay until May 21, 2010.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers. Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site at

    Contact Information:

    Michael Aberman, M.D.               Peter Dworkin
    Investor Relations                  Corporate Communications
    914.345.7799                        914.345.7640

SOURCE Regeneron Pharmaceuticals, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved